HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aeolus Pharmaceuticals, Inc.

https://www.aeoluspharma.com/

Latest From Aeolus Pharmaceuticals, Inc.

US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA

Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.

Drug Approval Standards Drug Review

US FDA’s Most Controversial Drug Approval Decisions, From A To Z

Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.

Approvals Drug Approval Standards

US FDA’s Most Controversial Drug Approval Decisions, From A To Z

With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.

FDA Drug Approval Standards

Finance Watch: Roivant To Go Public In SPAC Merger, Raise $611m

Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.

Finance Watch Deals
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Incara Pharmaceuticals
UsernamePublicRestriction

Register